Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar 26;9(1):66.
doi: 10.1186/s13643-020-01306-9.

Prognosis of PD-L1 in human breast cancer: protocol for a systematic review and meta-analysis

Isnard Elman Litvin  1   2 , Machline Paim Paganella  3 , Eliana Marcia Wendland  4 , Adriana Vial Roehe  5
Affiliations

Prognosis of PD-L1 in human breast cancer: protocol for a systematic review and meta-analysis

Isnard Elman Litvin et al. Syst Rev. .

Abstract

Background: Breast cancer is one of the most common malignancies in women worldwide, and one of the leading causes of cancer-related death. Programmed cell death 1 (PD-1) and its ligand (PD-L1) are key physiologic suppressors of the cytotoxic immune reaction. Some authors advocate that PD-L1 expression may help in breast cancer prognosis.

Methods: We will conduct a systematic review of observational or interventional studies evaluating the prognostic ability of PD-L1 expression levels in predicting positive clinical outcomes in Human Breast Cancer. A sensitive search strategy will be employed in MEDLINE, EMBASE, LILACS, The Grey Literature Report, OpenGrey, OAIster, and Cochrane CENTRAL. Two reviewers will independently screen all identified references for eligibility and extract data. The outcomes evaluated will be Overall Survival, Breast Cancer-specific Survival, Disease-free Survival, Recurrence-free Survival, Positive Lymph Node, and Distant Metastasis. The outcomes will be extracted directly from the studies, if available. Methodological quality and bias of included studies will be assessed using a standardized checklist and overall quality of evidence will be assessed through the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. If meta-analysis is possible, the measures of association will be calculated using bivariate random-effects models. Statistical heterogeneity will be evaluated with I2 statistics and explored through sensitivity analysis.

Discussion: Immunomodulation seems to be a promising strategy in solid tumors. Breast cancer is the most common malignancies in women worldwide, and one of the leading causes of cancer death. PD-1 and PD-L1 are key physiologic suppressors of the cytotoxic immune reaction.

Trial registration: Systematic review registration: CRD42019121118 (PROSPERO).

Keywords: Human Breast Cancer; Meta-analysis; PD-L1; Protocol; Systematic Review.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

References

    1. Andre F, Dieci M V., Dubsky P, Sotiriou C, Curigliano G, Denkert C, et al. Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer. Clin Cancer Res. 2013 19(1):28–33. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23258741. - PubMed
    1. Mao Y, Qu Q, Chen X, Huang O, Wu J, Shen K. The Prognostic Value of Tumor-Infiltrating Lymphocytes in Breast Cancer: A Systematic Review and Meta-Analysis. PLoS One. 2016;11(4):e0152500. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27073890. - PMC - PubMed
    1. Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013 31(7):860–867. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23341518. - PubMed
    1. Mahmoud SMA, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AHS, et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 2011;29(15):1949–1955. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21483002. - PubMed
    1. Ménard S, Tomasic G, Casalini P, Balsari A, Pilotti S, Cascinelli N, et al. Lymphoid infiltration as a prognostic variable for early-onset breast carcinomas. Clin Cancer Res. 1997 ;3(5):817–819. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9815754. - PubMed